Skip to main content

Published locations for FDA approves bimekizumab for moderate to severe plaque psoriasis in adults

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves bimekizumab for moderate to severe plaque psoriasis in adults

User login

  • Reset your password
  • /content/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis-adults
  • /edermatologynews/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis
  • /familypracticenews/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque
  • /fedprac/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis-adults
  • /internalmedicinenews/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque
  • /rheumatologynews/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis
  • /rheumatology/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis
  • /internalmedicine/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis
  • /dermatology/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis
  • /familymedicine/article/266021/psoriasis/fda-approves-bimekizumab-moderate-severe-plaque-psoriasis
  • /rheumatology/psoriatic-arthritis-resource-center/article/266021/psoriasis/fda-approves-bimekizumab